EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Executive Employment Agreement (the “Agreement”) is made and entered into as of June 30, 2018 by and between Aquestive Therapeutics, Inc. (the “Company”) and Keith J. Kendall (the “Executive”).
DATED AUGUST 15, 2008Commercial Exploitation Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, RB wishes to engage MSX to manufacture and supply the Products (as defined below) on the terms of this Agreement and MSX wishes to manufacture and supply the Products to RB on the terms of this Agreement.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”), dated as of September 24, 2017, is by and between MonoSol Rx, LLC, a Delaware limited liability company (“MonoSol”); and Indivior Inc., a Delaware corporation, and Indivior UK Limited, a corporation organized under the laws of England and Wales, as successors in interest to Reckitt Benckiser Pharmaceuticals Inc. and RB Pharmaceuticals Limited, respectively (collectively, “Indivior”).
STOCK OPTION AGREEMENT UNDER THE AQUESTIVE THERAPEUTICS, INC.Stock Option Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK OPTION AGREEMENT (this “Agreement”) between Aquestive Therapeutics, Inc. (the “Corporation” or the “Company”) and the individual specified on the Notice of Grant (the “Optionee”) is made as of the date of grant specified on the Notice of Grant to which this Agreement is attached (the “Grant Notice”). The date of grant specified on the Grant Notice is referred to herein as the “Grant Date.”
Common Stock, $0.001 par value per share UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
AQUESTIVE THERAPEUTICS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of [●] shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to the several underwriters (collectively, the “Underwriters”) named in Schedule I to this agreement (this “Agreement”), for whom BMO Capital Markets Corp. (“BMOCM”) and RBC Capital Markets, LLC are acting as representatives (the “Representatives”). The Company has also agreed to grant to the Underwriters an option (the “Option”) to purchase an aggregate of up to [●] additional shares of Common Stock (the “Option Shares”) on the terms set forth in Section 1(b) hereof. The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”
RESTRICTED STOCK UNIT AGREEMENT UNDER THE AQUESTIVE THERAPEUTICS, INC.Restricted Stock Unit Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) between Aquestive Therapeutics, Inc. (“Aquestive”) and the individual specified on the Notice of Grant (the “Grantee”) is made as of the date of grant specified on the Notice of Grant to which this Agreement is attached (the “Grant Notice”). The Date of Grant specified on the Grant Notice is referred to herein as the “Grant Date.”
